Kezar Life Sciences Inc (KZR NASDAQ) stock market data APIs
$3.7452
0.09(2.4%)
as of September 18, 2025
Try our APIs with
free plan!
Kezar Life Sciences Inc Financial Data Overview
Price chart is built with
Anychart
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b/2 clinical trials in systemic lupus erythematosus. It is also developing KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Prev. Close
3.7452
Open
3.8311
High
3.8509
Low
3.7427
52 wk Range
3.6201-9.18
Market Cap
27 535 K
Shares Outstanding
7 323 K
EPS
-1.87
Beta
0.605
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Kezar Life Sciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kezar Life Sciences Inc data using free add-ons & libraries
Get Kezar Life Sciences Inc Fundamental Data
Kezar Life Sciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -74 738 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-13
- EPS/Forecast: -0.28
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kezar Life Sciences Inc News
New
Highlights – June Quarter 2025
Novo completed its maiden RC drill program at the Clone prospect as part of the Tibooburra Gold Project in May 2025 testing 500 m of strike. Drilling produced significant high-grade gold intercepts in...
Kezar : FDA Lifts Partial Clinical Hold On Phase 2a Trial Of Zetomipzomib In Autoimmune Hepatitis
(RTTNews) - Kezar Life Sciences Inc. (KZR) announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration has lifted the partial clinical hold on the completed PORTOL...
Kezar Life Sciences stock gains after FDA lifts partial clinical hold
Investing.com -- Kezar Life Sciences Inc (NASDAQ:KZR) stock gained 4% after the FDA lifted a partial clinical hold on its completed Phase 2a trial evaluating zetomipzomib in patients with autoimmune...
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
In this article, we will take a look at the 13 best penny stocks to buy according to billionaire Ken Griffin. To see more such companies, go directly to 5 Best Penny Stocks to Buy According to Billion...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
